Condition: Head and Neck Squamous Cell Carcinoma · Sponsor: West China Hospital
The purpose of this study is to explore the safety and feasibility of anti-programmed cell death protein 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6 blockade, Dalpiciclib, as a new neoadjuvant treatment regimen for patients with resectable head and neck squamous cell carcinoma(HNSCC).
This description comes directly from the study's public registry record.
Jin Zhou, MD.,PhD. · +8613880626596 · zhoujin096@scu.edu.cn
Shangwei Sun · +8615291996883 · sunshangwei@stu.scu.edu.cn
Always discuss trial participation with your own doctor first.
| West China Hospital, Sichuan University | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06109207